Literature DB >> 34228177

Ablation therapy of postural orthostatic tachycardia syndrome, inappropriate sinus tachycardia and primary electrical diseases: new insights in invasive treatment options in severely symptomatic patients.

Cinzia Monaco1, Antonio Sorgente1, Robbert Ramak1, Gian Battista Chierchia1, Mark La Meir2, Carlo de Asmundis3.   

Abstract

Achieving the goal management of some arrhythmic syndromes can be challenging; medical treatment for inappropriate sinus tachycardia (IST) and postural orthostatic tachycardia syndrome (POTS) may be ineffective, necessitating multidisciplinary team treatment. Implantable defibrillator devices (ICDs), along with anti-arrhythmic drugs (AADs), remain the first-line treatment for primary electrical diseases that pose a risk of sudden cardiac death (SCD). Ablation of the arrhythmogenic substrate is not always suggested in patients with these pathologies, but it may be a valuable support for reducing arrhythmic burden, improving quality of life, and treating pathologies that are resistant to pharmacological treatment; however, this option is not often considered due to the potential risks associated with an invasive approach. Minimally invasive hybrid ablation in these syndromes, such as a hybrid thoracoscopic approach and the use of non-invasive mapping systems, reduces post-surgery complications and ensures the best possible outcome for the patient.

Entities:  

Keywords:  Arrhythmogenic substrate ablation; Electrocardiographic mapping; IST; POTS; Thoracoscopic hybrid ablation

Year:  2021        PMID: 34228177     DOI: 10.1007/s00399-021-00778-z

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  4 in total

Review 1.  Primary electrical diseases diagnosis, genetic and management.

Authors:  P Maury; A Duparc; P Mondoly; A Rollin; C Cardin; M Delay
Journal:  Minerva Cardioangiol       Date:  2010-08       Impact factor: 1.347

Review 2.  Electrocardiographic imaging of the arrhythmogenic substrate of Brugada syndrome: Current evidence and future perspectives.

Authors:  Alessio Galli; Alessandro Rizzo; Cinzia Monaco; Francesca Salghetti; Oriana Scala; Gian Battista Chierchia; Mark La Meir; Pedro Brugada; Carlo de Asmundis
Journal:  Trends Cardiovasc Med       Date:  2020-06-15       Impact factor: 6.677

3.  Midterm clinical outcomes of concomitant thoracoscopic epicardial and transcatheter endocardial ablation for persistent and long-standing persistent atrial fibrillation: a single-centre experience.

Authors:  Carlo de Asmundis; Gian-Battista Chierchia; Giacomo Mugnai; Ines Van Loo; Jan Nijs; Jens Czapla; Giulio Conte; Vedran Velagic; Moises Rodrigues Mañero; Giuseppe Ciconte; Erwin Ströker; Vincent Umbrain; Jan Poelaert; Pedro Brugada; Mark La Meir
Journal:  Europace       Date:  2016-05-31       Impact factor: 5.214

4.  Concomitant thoracoscopic left cardiac sympathectomy and RVOT epicardial ablation of the arrhythmogenic substrate in a patient with Long QT and Brugada syndromes related to uncommon sodium channel beta-subunit mutation.

Authors:  Cinzia Monaco; Alessio Galli; Gian Battista Chierchia; Federico Cecchini; Mark La Meir; Pedro Brugada; Carlo de Asmundis
Journal:  Pacing Clin Electrophysiol       Date:  2021-03-17       Impact factor: 1.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.